AzTrials
AzTrials

SchizophreniaNCT06515522

A Biological Signature for the Early Differential Diagnosis of Psychosis

An observational study of Schizophrenia and Bipolar Disorder, run by IRCCS San Raffaele.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden. Although they are identified as distinct disorders, the potential overlapping symptomatology poses important challenges for the differential diagnosis. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
differential diagnosis
How many people
1,850 participants
Where
No sites listed yet
Study dates
31 Aug 2024to Aug 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Adult, Older adult

Study population: Psychiatric patients with a diagnosis of Schizophrenia or Bipolar disorder or Major depressive disorder, neuroimaging data and peripheral blood sampling. Healthy controls with neuroimaging data and peripheral blood sampling

Who may be able to join

  • Aged 18-65
  • diagnosed with Schizophrenia, Bipolar Disorder or Major depressive disorder.
  • For Bipolar and Major depressive disorder, Hamilton Depression Rating Scale scores >8
  • Multimodal 3 T MRI acquisition available (*)
  • Genetic and serum inflammatory data available, or serum and whole blood available for genotyping and inflammatory markers determination.

Who cannot join

  • Presence of major medical or neurological disorders
  • Alcohol or drugs abuse or dependence
  • Conditions known to alter immune-inflammatory status, such as rheumatic diseases, malignancies,
  • ongoing treatment with drugs acting on the immune system, such as corticosteroids, NSAIDs and other immunomodulatory drugs.
  • Pregnancy or lactating

Trial locations and contacts

No sites are listed yet.

Francesco Benedetti, Prof contact

00390226433156

benedetti.francesco@hsr.it

Sara Poletti, PhD contact

00390226436833

poletti.sara@hsr.it

About this study

Official title: A Biological Signature for the Early Differential Diagnosis of Psychosis: Unveiling the Differences Between Mood Disorders and Schizophrenia With Multimodal Machine Learning Techniques

Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden. Although they are identified as distinct disorders, the potential overlapping symptomatology poses important challenges for the differential diagnosis. A consistent literature affirms that brain structure, and function reflect an intermediate phenotype of an underlying genetic vulnerability for the disorders, shaped by interaction with environmental experiences. Such experiences include early life stress and trauma which seem to characterize psychiatric patients and have been associated with brain abnormalities. Further, early life experiences have been associated with inflammation in a subpopulation of psychiatric patients However imaging, inflammatory, and genetic group-level differences, albeit consistent, do not impact clinical practice since they have not been translated into individual prediction. To address these issues, a rapidly growing body of scientific literature implemented computational techniques, such as machine learning (ML). In this project we will develop cutting-edge ML algorithms to predict the differential diagnosis between mood disorders and SZ from genetic, neuroimaging, inflammatory and environmental data in a unique cohort of 1850 patients and 1000 healthy controls recruited in 4 different centers in Italy. The project will address three different aims: in aim 1 we will develop algorithms for the differential diagnosis between SZ and MD combining multimodal neuroimaging and genetic data; in aim 2 we will predict the differential diagnosis between SZ and MD from immuno-inflammatory and environmental data; finally, with aim three we will exploit an animal model to identify the underlying mechanisms of brain alterations associated with exposure to early life stress. Machine learning analyses will include algorithms for data harmonization and feature reduction, as well as for generating normative models. Finally. different classifying models will be compared considering the specific features to achieve the best performance.The definition of reliable and objective biomarkers, combined with cutting-edge computational methodology, could help clinicians in providing more precise diagnoses and early interventions, also considering dimensional constructs \& factors influencing outcomes such as affective vs non-affective psychosis and breadth of exposure to traumatic events

Being tested
differential diagnosis
Medical subject headings
Schizophrenia, Bipolar Disorder, Depressive Disorder, Major

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • differential diagnosisOther

    this is a retrospective observational study. no intervention has been or will be performed

Study groups in NCT06515522
Study groupRoleWhat they receive
SchizophreniaAll patients with schizophrenia recruited from 2007 and 2023
Receives: Other: differential diagnosis
Mood disordersAll patients with bipolar or major depressive disorders recruited from 2007 and 2023
Receives: Other: differential diagnosis
Controlshealthy controls
Receives: Other: differential diagnosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Schizophrenia vs Mood disorders

    Predicting the differential diagnosis between Schizophrenia and Mood Disorders combining multimodal neuroimaging, immuno-inflammatory and genetic data

    Measured: baseline

Secondary outcomes (1)
  1. Bipolar vs major depressive disorder

    Predicting the differential diagnosis between major depression and bipolar disorder, and the presence or absence of psychotic symptoms combining multimodal neuroimaging, immuno-inflammatory and genetic data

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2024
  2. Study start31 Aug 2024 (estimated)
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
1,850 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06515522
Sponsor's protocol ID
PNRR-MCNT2-2023-12378015
Status last verified
Jul 2024
First submitted
17 Jul 2024
Last updated
23 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Schizophrenia and Bipolar Disorder, run by IRCCS San Raffaele.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Francesco Benedetti, Prof (00390226433156, benedetti.francesco@hsr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Schizophrenia vs Mood disorders (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in